A report that champions the UK medicine manufacturing industry has featured the iMATCH project as one of its key case studies. The report that focused on the Medicines Manufacturing Challenge (MMC) detailed how incentives such as the MMC have allowed the UK to become a leading global hub for the development, production and delivery of cutting-edge therapies. Established in 2017, the MMC has since invested £255 million into the UK medicine manufacturing sector; allowing a development of new technology, new infrastructure and establishing a culture of collaboration across UK life sciences.
Whilst the COVID 19 vaccine rollout is the most current product of incentives coming through the MMC, the development of advanced therapies such as the iMATCH project have also been given as an example for how the UK can now become a world-leading site for producing the next generation of advanced therapies. It was through the MMC and their £12 million investment that allowed the expansion of the Cell and Gene Therapy Catapult Manufacturing Centre, ensuring more projects like iMATCH could continue to be developed.
‘‘Thanks to the groundwork laid by the Medicines Manufacturing Challenge, we are now offering lifechanging therapies to many more patients.’ Fiona Thistlethwaite, The Christie NIHR CRF Director and Medical Oncology Consultant, iMATCH Director